GlassScriptPhysician profile
Isabel C Hamro
NPI 1013420736
$2,133.75
in general payments reported to CMS, 2019-2025
15 companies · $1,169 in 2025
The $1,169 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $965 · 2025: $1,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,114 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,114.45 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $502.59 | 2024-2025 | |
| Madrigal Pharmaceuticals | $290.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $256.19 | 2024-2025 | Tremfya, Stelara |
| Aimmune Therapeutics, INC. | $188.93 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $150.01 | 2025 | Zepbound |
| Ardelyx, INC. | $138.66 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $129.88 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $124.93 | 2024 | Zeposia |
| Bayer Healthcare Pharmaceuticals INC. | $109.85 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.69 | 2024-2025 | Eohilia |
| Ipsen Biopharmaceuticals, INC | $55.01 | 2025 | Iqirvo |
| Novo Nordisk INC | $43.24 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $34.41 | 2025 | Onpattro |
| Intercept Pharmaceuticals, INC. | $22.54 | 2025 | |
| Merck Sharp & Dohme LLC | $18.74 | 2025 | Vaqta, Gardasil 9, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabel Hamro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.